BioPharmSignal logoBioPharmSignal

Biotech News

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

Synlogic (SYBX)SynlogicFinancing

Combined company to operate as Caldera Therapeutics, developing CLD-423, a potential first-in-class TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease and other immune-mediated diseases Concurrent upsized $278 million private placement committed by a syndicate of leading healthcare

Related news

VKTXViking Therapeutics2026-09-24 11:05 EST

Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

MNKDMannKind2026-07-24 10:35 EST

MannKind Announces $50 Million Private Placement

MLYSMineralys Therapeutics2026-06-03 10:05 EST

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

SGMTSagimet Biosciences2026-09-30 10:19 EST

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

SGMTSagimet Biosciences2026-10-01 20:31 EST

Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

MLYSMineralys Therapeutics2026-06-03 10:00 EST

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

VKTXViking Therapeutics2026-09-28 20:30 EST

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes

ALGSAligos Therapeutics2026-07-30 12:00 EST

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

ALGSAligos Therapeutics2026-08-06 12:00 EST

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results

ALTAltimmune2026-05-27 12:00 EST

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

View all latest news

Synlogic

Synlogic was a synthetic-biology company focused on engineered microbes and metabolic disease before its restructuring and decline. Its platform aimed to use living medicines to address rare disorders.

Recent company news

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

SYBXSynlogic2024-11-12 21:35 EST

Synlogic Reports Third Quarter 2024 Financial Results

SYBXSynlogic2024-08-08 11:00 EST

Synlogic Reports Second Quarter 2024 Financial Results

SYBXSynlogic2024-05-14 11:00 EST

Synlogic Reports First Quarter 2024 Financial Results

SYBXSynlogic2024-03-19 11:00 EST

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Stock data

Close
1.11 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States